Cystic fibrosis: year in review.
Cystic fibrosis: year in review.
复制标题
囊性纤维化：年度回顾。
DOI：
10.1097/mcp.0b013e32833f3f0d
复制
发表时间：
2010
影响因子：
3.3
通讯作者：
M. Boyle
中科院分区：
文献类型：
--
作者：
M. Boyle
对于囊性纤维化(CF)患者和照顾者来说，去年是令人兴奋的一年。从产前和新生儿筛查(NBS)成为一种日益被接受的护理标准，到新的CF相关糖尿病(CFRD)指南，强调CFRD在30岁以上的CF成年人中约50%的患病率，新的护理方法在整个CF年龄段都是显而易见的。关键的临床试验已经开始，这些试验不仅寻求解决CF的症状或并发症，而且利用针对基因型的治疗来解决潜在的CF跨膜电导调节(CFTR)功能障碍。在全球范围内，CF护理中心一直专注于优化治疗实践和护理交付，以确保他们的患者获得最佳结果。
The last year has been an exciting one for cystic fibrosis (CF) patients and caregivers. New approaches to care have been evident throughout the CF age spectrum: from prenatal and newborn screening (NBS) becoming an increasingly accepted standard of care, to new guidelines for CF-related diabetes (CFRD) which highlight the approximately 50% prevalence of CFRD in CF adults over the age of 30. Pivotal clinical trials have commenced which do not just seek to address symptoms or complications of CF, but utilize genotype-specific therapies to address underlying CF transmembrane conductance regulator (CFTR) dysfunction. Around the globe CF care centers have focused on optimizing treatment practices and care delivery to assure best outcomes for their patients.